Medicine information · No products for sale
Wegovy: Semaglutide Medicine Information
Factual information about Wegovy, a semaglutide-containing prescription medicine.
Published 20 October 2026 · Last reviewed 20 October 2026 · Editorial content by the Peptide Atelier UK team, not clinically reviewed
Editorial standards and corrections
Educational information only. Wegovy is a prescription-only medicine. Peptide Atelier UK does not sell, supply or prescribe it. This page is not medical advice; speak to a GP, pharmacist or other qualified healthcare professional.
Active ingredient
Wegovy contains semaglutide, a GLP-1 receptor agonist. It is manufactured by Novo Nordisk and given as a once-weekly injection using a pre-filled pen.
Authorised uses
Wegovy is authorised for weight management in adults who meet specific body mass index criteria, alongside a reduced-calorie diet and increased physical activity, and in some adolescents. It is also authorised to reduce the risk of major cardiovascular events in certain adults. Full details are in the official Summary of Product Characteristics.
How Wegovy differs from Ozempic
Ozempic also contains semaglutide but is authorised for type 2 diabetes and uses different doses. The two are not interchangeable.
Clinical assessment
A prescriber will consider your medical history, other medicines, and any reasons the medicine may be unsuitable. Ongoing review is part of safe treatment.